<DOC>
	<DOCNO>NCT01214889</DOCNO>
	<brief_summary>This study design assess immunogenicity safety PENTAXIM™ combine vaccine versus TETRAXIM™ vaccine support registration PENTAXIM™ South Korea . Primary Objective : To demonstrate non-inferiority term seroprotection rate ( Diphtheria , Tetanus , Polio type 1 , 2 3 , Polyribosyl Ribitol Phosphate [ PRP ] ) vaccine response rate acellular Pertussis antigens sanofi pasteur 's PENTAXIM™ vaccine versus sanofi pasteur 's TETRAXIM™ Act ( Haemophilus influenzae type b ) HIB™ vaccine , one month three-dose primary vaccination .</brief_summary>
	<brief_title>Study PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine South Korean Infants .</brief_title>
	<detailed_description>All participant receive three primary dos assign study vaccine , Days 0 , 60 , 120 . They assess immunogenicity Day 0 vaccination Day 150 post-vaccination . Safety assess participant throughout study , Day 157 .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 month ( 56 70 day ) inclusive day inclusion Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg Informed consent form sign parent ( ) legal representative Able attend schedule visit comply trial procedure Participation another clinical trial 4 week precede trial inclusion Planned participation another clinical trial present trial period Congenital acquire immunodeficiency , immunosuppressive therapy long term systemic corticosteroid therapy Systemic hypersensitivity vaccine component history life threaten reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion Blood blood derive product receive past current plan administration trial ( include immunoglobulin ) . Any vaccination 3 week precede first trial vaccination . History diphtheria , tetanus , pertussis , poliomyelitis , Haemophilus influenzae type b infection ( confirm either clinically , serologically microbiologically ) . Clinical known serological evidence systemic illness include Hepatitis B , Hepatitis C and/or Human Immunodeficiency Virus ( HIV ) infection Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis disease Haemophilus influenzae type b infection trial vaccine another vaccine . Thrombocytopenia bleed disorder contraindicate intramuscular vaccination History of/current major neurological disease seizure . Febrile illness ( axillary temperature ≥ 38ºC ) acute illness day inclusion . Known family history congenital genetic immunodeficiency .</criteria>
	<gender>All</gender>
	<minimum_age>56 Days</minimum_age>
	<maximum_age>70 Days</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Haemophilus influenzae type B</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>PENTAXIM™</keyword>
	<keyword>TETRAXIM™</keyword>
</DOC>